AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
Phase 2
Completed
- Conditions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 116
- Registration Number
- NCT06057064
- Locations
- 🇷🇺
Research Site, St Petersburg, Russian Federation
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06053424
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT06046534
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 33
- Registration Number
- NCT06042049
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Completed
- Conditions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT06039683
- Locations
- 🇦🇪
Research Site, Al Ain, United Arab Emirates
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06040099
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1240
- Registration Number
- NCT06040086
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 720
- Registration Number
- NCT06034743
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
PRostate Olaparib Real World Evidence Study
Recruiting
- Conditions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06031805
- Locations
- 🇫🇷
Research Site, Vantoux, France
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 372
- Registration Number
- NCT06023589
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath